Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Mount Sinai School of Medicine |
---|---|
Information provided by: | Office of Rare Diseases (ORD) |
ClinicalTrials.gov Identifier: | NCT00004479 |
OBJECTIVES:
Determine the efficacy of midodrine, a selective alpha 1 adrenergic agonist, in preventing neurally mediated syncope.
Condition | Intervention |
---|---|
Syncope |
Drug: midodrine |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind |
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics-- Diagnosis of neurally mediated syncope (vasovagal fainting) Sudden fall in blood pressure AND Slowing of the heart AND Temporary loss of consciousness AND Hemodynamic response to head up tilt --Prior/Concurrent Therapy-- No other concurrent adrenergic agonist or antiagonist --Patient Characteristics-- Fertile patients must use effective birth control
United States, New York | |
Mount Sinai School of Medicine | |
New York, New York, United States, 10029 |
Study Chair: | Horacio Kaufmann | Mount Sinai School of Medicine |
Study ID Numbers: | 199/14181, MTS-GCO-97-160NE, ROBERTS-MTS-GCO-97-160NE |
Study First Received: | October 18, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00004479 |
Health Authority: | Unspecified |
neurologic and psychiatric disorders rare disease syncope |
Signs and Symptoms Unconsciousness Mental Disorders Consciousness Disorders Midodrine |
Rare Diseases Neurologic Manifestations Neurobehavioral Manifestations Syncope |
Neurotransmitter Agents Adrenergic alpha-Agonists Adrenergic Agents Molecular Mechanisms of Pharmacological Action Sympathomimetics Nervous System Diseases Physiological Effects of Drugs |
Cardiovascular Agents Adrenergic Agonists Pharmacologic Actions Autonomic Agents Therapeutic Uses Vasoconstrictor Agents Peripheral Nervous System Agents |